VRPX: Virpax Pharmaceuticals Inc. Company Short-Term Debt

Symbol and logo of brand Virpax Pharmaceuticals, Inc. (VRPX)

Virpax Pharmaceuticals (VRPX) utilizes an asset-light approach, licensing adapted molecules for nasal sprays to major players without constructing its own plants. The company develops innovative non-opioid treatments for CNS therapy and pain management, leveraging advanced delivery systems. The current metric stands at 0.00. This price trajectory for the securities on the GURU.Markets platform illustrates the price action of this biopharmaceutical developer.

VRPX (virpaxpharma.com) Company Short-Term Debts history from 07/04/2022 to 04/13/2025

Comprehensive metric breakdowns and analytics for Virpax Pharmaceuticals Inc. (VRPX)

- current quotes and average value forecast:
Price Chart Virpax|VRPX - Fair Value Consensus
- market capitalization information:
Market Value Virpax Pharmaceuticals, Inc.|VRPX - Real Price to Acquire Entire Company
- shareholders' equity book value data:
Book Value per Share Virpax Pharmaceuticals|VRPX - Book Capitalization|Market Cap to Net Assets Ratio virpaxpharma.com|VRPX - Aggregate Asset Value
- debt and liquidity data:
Debt to Equity Virpax Pharmaceuticals|VRPX - Long-Term Liabilities to Equity|Short-Term Debt to Equity Virpax|VRPX - Company Total Debt Obligations|Debt to Book Value Virpax Pharmaceuticals, Inc.|VRPX - Long-Term Debt|Company Short-Term Debts Virpax Pharmaceuticals|Quick Ratio virpaxpharma.com
- net income and valuation multiples indicators:
VRPX - Final Profit
Fundamental company analysis:virpaxpharma.com - VRPX
Mass-produced product of Virpax

For Virpax Pharmaceuticals (VRPX), which develops innovative non-opioid analgesic delivery systems, this indicator tracks the aggregate volume of liabilities with a maturity of up to one year. Analyzing current debt on loans and borrowings allows for an assessment of liquidity risks and the balance between financial stability and the efficiency of R&D investments, preventing capital losses in the intervals between quarterly reports.

Main competitors

ALKS - Company Short-Term Debt|Company Short-Term Loans and Borrowings AVDL (Avadel Pharmaceuticals PLC)|atai Life Sciences Corp (ATAI) - Company Short-Term Debt|Company Current Liabilities GH Research Group|MNMD (Mind Medicine) - Company Short-Term Debts|Company Short-Term Debts compasspathways.com|Company Current Liabilities LBRX (LB Pharmaceuticals)|DRUG (Bright Minds Bio) - Company Short-Term Loans and Borrowings|Company Short-Term Debt Vanda Pharmaceuticals Inc VNDA|CYBN (Cybin Inc) - Current Liabilities|ANRO - Company Short-Term Debt|Short-Term Debt Volume nrxpharma.com NRXP|CING (cingulate.com) - Company Current Liabilities|Short-Term Debt Silo Pharma Inc. (SILO)|CPHI (China Pharma Holdings Inc.) - Company Short-Term Debts|Company Current Liabilities clearmindmedicine.com (CMND)|Company Short-Term Debts PBM|SPRC (scisparc.com) - Company Short-Term Loans and Borrowings|Company Short-Term Debt Seelos Therapeutics, Inc. SEEL|Karuna Therapeutics Inc (KRTX) - Short-Term Debt